Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction

Neurourology and Urodynamics

Volumn 29, Issue 5, 2010, Pages 741-747

  Kraus, Stephen R ^a   Dmochowski, Roger ^b   Albo, Michael E ^c   Xu, Lei ^d   Klise, Suzanne R ^d   Roehrborn, Claus G ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Benign prostatic obstruction; Lower urinary tract symptoms; Multicenter trials; Standardization; Tadalafil; Urodynamic study

Indexed keywords

PLACEBO; TADALAFIL;

ARTICLE; BLADDER PRESSURE; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR MUSCLE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARDIZATION; TEST RETEST RELIABILITY; TRAINING; URINE FLOW RATE; URODYNAMICS; UROFLOWMETRY;

CARBOLINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATISM; REFERENCE STANDARDS; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS;

EID: 77956813557     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20825     Document Type: Article

References (10)

1. Schafer W, Abrams P, Liao L, et al. 2002; Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21:261-274
2. Schafer W, de la Rosette JJ, Hofner K, et al. 1994; The ICS-BPH study: Pressure flow studies, quality control and initial analysis. Neurourol Urodyn 13:491-492
3. Lewis P, Abrams P. 2000; Urodynamic protocol and central review of data for clinical trials in lower urinary tract dysfunction. BJU Int 85:20-30.
4. Hashim H, Elhilali M, Bjerklund Johansen TE, et al. 2007; The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement. Eur Urol 52:1186-1193
5. Sullivan J, Lewis P, Howell S, et al. 2003; Quality control in urodynamics: A review of urodynamic traces from one centre. BJU Int 91:201-207
6. Abrams P, Cardozo L, Fall M, et al. 2002; The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21: 167-178 (Pubitemid 34195211)
7. Abrams P. 1999; Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: Three simple indices to define bladder voiding function. BJU Int 84:14-15
8. Abrams P, Kaplan S, De Koning Gans HJ, et al. 2006; Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175:999-1004. (Pubitemid 43200054)
9. Tammela TL, Schafer W, Barrett DM, et al. 1999; Repeated pressure-flow studies in the evaluation of bladder outlet obstruction due to benign prostatic enlargement. Finasteride Urodynamics Study Group. Neurourol Urodyn 18:17-24.
10. Nager CW, Albo ME, Fitzgerald MP, et al. 2007; Process for development of multicenter urodynamic studies. Urology 69:63-67